Alembic
Touching Lives over 100 years

Date: 7th May, 2025

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code: 533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 and Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Publication of Audited Financial Results

With reference to the captioned subject, we enclose herewith Newspaper cuttings of Extract of Audited Financial Results for the quarter and financial year ended 31st March, 2025, published in 'Economic Times, Indian Express, Business Standard and The Times of India (English Edition) and Divya Bhaskar and Financial Express (Gujarati Edition)' on 7th May, 2025.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Alembic Pharmaceuticals Limited

Manisha Saraf
Company Secretary

Encl.: A/a.

Alembic
Touching Lives over 100 years

ALEMBIC PHARMACEUTICALS LIMITED

CIN: L24230GJ2010PLC061123
Regd.Office: Alembic Road, Vadodara - 390 003
Tel.: 0265 6637000
E-mail: apl.investors@alembic.co.in
Website: www.alembicpharmaceuticals.com

Extract of statement of Consolidated Audited Financial Results for the quarter & year ended 31st March, 2025

(₹ in Crores except per share data)

Particulars	Quarter Ended		Year Ended
	31.03.2025 (Audited)	31.03.2024 (Audited)	31.03.2025 (Audited)
Total Income from Operations	**1,769.64**	1,516.98	6,672.08
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	**191.95**	182.85	694.31
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	**191.95**	182.85	707.18
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items)	**156.89**	178.21	583.42
Total Comprehensive Income for the period	**162.17**	166.70	587.54
Equity Share Capital	**39.31**	39.31	39.31
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	—	—	5,151.63
Earning Per Share (Face Value of ₹2/- each) Basic & Diluted	**7.98**	9.07	29.68

Notes:

1.

Standalone details	Quarter Ended		Year Ended
	31.03.2025 (Audited)	31.03.2024 (Audited)	31.03.2025 (Audited)
Income from Operations	**1,570.64**	1,474.55	6,032.63
Profit Before Tax	**91.56**	216.16	595.72
Profit After Tax	**75.34**	201.87	503.12

2. The above is an extract of the detailed format of the audited financial results filed with the Stock Exchanges. The detailed Financial Results are available on the Stock Exchange's website at www.nseindia.com and www.bseindia.com and Company's website (URL: https://alembicpharmaceuticals.com/quarterly-results). The same can also be accessed by scanning the Quick Response (QR) Code provided below.

For Alembic Pharmaceuticals Limited
Sd/-
Chirayu Amin
Chairman and CEO

Place : Vadodara
Date : 6th May, 2025

Alembic
Touching Lives over 100 years

ALEMBIC PHARMACEUTICALS LIMITED
CIN: L24230GJ2010PLC061123
Regd.Office: Alembic Road, Vadodara - 390 003
Tel.: 0265 6637000
E-mail: apl.investors@alembic.co.in
Website: www.alembicpharmaceuticals.com

Extract of statement of Consolidated Audited Financial Results for the quarter & year ended 31st March, 2025

(₹ in Crores except per share data)

Particulars	Quarter Ended		Year Ended
	31.03.2025 (Audited)	31.03.2024 (Audited)	31.03.2025 (Audited)
Total Income from Operations	**1,769.64**	1,516.98	6,672.08
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	**191.95**	182.85	694.31
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	**191.95**	182.85	707.18
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items)	**156.89**	178.21	583.42
Total Comprehensive Income for the period	**162.17**	166.70	587.54
Equity Share Capital	**39.31**	39.31	39.31
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	—	—	5,151.63
Earning Per Share (Face Value of ₹2/- each) Basic & Diluted	**7.98**	9.07	29.68

Notes:

1.

Standalone details	Quarter Ended		Year Ended
	31.03.2025 (Audited)	31.03.2024 (Audited)	31.03.2025 (Audited)
Income from Operations	**1,570.64**	1,474.55	6,032.63
Profit Before Tax	**91.56**	216.16	595.72
Profit After Tax	**75.34**	201.87	503.12

2. The above is an extract of the detailed format of the audited financial results filed with the Stock Exchanges. The detailed Financial Results are available on the Stock Exchange's website at www.nseindia.com and www.bseindia.com and Company's website (URL: https://alembicpharmaceuticals.com/quarterly-results). The same can also be accessed by scanning the Quick Response (QR) Code provided below.

For Alembic Pharmaceuticals Limited
Sd/-
Chirayu Amin
Chairman and CEO

Place : Vadodara
Date : 6th May, 2025

Alembic
Touching Lives over 100 years

ALEMBIC PHARMACEUTICALS LIMITED
CIN: L24230GJ2010PLC061123
Regd.Office: Alembic Road, Vadodara - 390 003
Tel.: 0265 6637000
E-mail: apl.investors@alembic.co.in
Website: www.alembicpharmaceuticals.com

Extract of statement of Consolidated Audited Financial Results for the quarter & year ended 31st March, 2025

(₹ in Crores except per share data)

Particulars	Quarter Ended		Year Ended
	31.03.2025 (Audited)	31.03.2024 (Audited)	31.03.2025 (Audited)
Total Income from Operations	**1,769.64**	1,516.98	6,672.08
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	**191.95**	182.85	694.31
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	**191.95**	182.85	707.18
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items)	**156.89**	178.21	583.42
Total Comprehensive Income for the period	**162.17**	166.70	587.54
Equity Share Capital	**39.31**	39.31	39.31
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	—	—	5,151.63
Earning Per Share (Face Value of ₹2/- each) Basic & Diluted	**7.98**	9.07	29.68

Notes:

1. **Standalone details**

	Quarter Ended		Year Ended
	31.03.2025 (Audited)	31.03.2024 (Audited)	31.03.2025 (Audited)
Income from Operations	**1,570.64**	1,474.55	6,032.63
Profit Before Tax	**91.56**	216.16	595.72
*Profit After Tax	**75.34**	201.87	503.12

2. The above is an extract of the detailed format of the audited financial results filed with the Stock Exchanges. The detailed Financial Results are available on the Stock Exchange's website at www.nseindia.com and www.bseindia.com and Company's website (URL: https://alembicpharmaceuticals.com/quarterly-results). The same can also be accessed by scanning the Quick Response (QR) Code provided below.

For Alembic Pharmaceuticals Limited
Sd/-
Chirayu Amin
Chairman and CEO

Place : Vadodara
Date : 6th May, 2025

Alembic
Touching Lives over 100 years

ALEMBIC PHARMACEUTICALS LIMITED

CIN: L24230GJ2010PLC061123
Regd.Office: Alembic Road, Vadodara - 390 003
Tel.: 0265 6637000
E-mail: apl.investors@alembic.co.in
Website: www.alembicpharmaceuticals.com

Extract of statement of Consolidated Audited Financial Results for the quarter & year ended 31st March, 2025

(₹ in Crores except per share data)

Particulars	Quarter Ended		Year Ended
	31.03.2025 (Audited)	31.03.2024 (Audited)	31.03.2025 (Audited)
Total Income from Operations	**1,769.64**	1,516.98	6,672.08
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	**191.95**	182.85	694.31
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	**191.95**	182.85	707.18
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items)	**156.89**	178.21	583.42
Total Comprehensive Income for the period	**162.17**	166.70	587.54
Equity Share Capital	**39.31**	39.31	39.31
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	—	—	5,151.63
Earning Per Share (Face Value of ₹2/- each) Basic & Diluted	**7.98**	9.07	29.68

Notes:

1.

Standalone details	Quarter Ended		Year Ended
	31.03.2025 (Audited)	31.03.2024 (Audited)	31.03.2025 (Audited)
Income from Operations	**1,570.64**	1,474.55	6,032.63
Profit Before Tax	**91.56**	216.16	595.72
Profit After Tax	**75.34**	201.87	503.12

2. The above is an extract of the detailed format of the audited financial results filed with the Stock Exchanges. The detailed Financial Results are available on the Stock Exchange's website at www.nseindia.com and www.bseindia.com and Company's website (URL: https://alembicpharmaceuticals.com/quarterly-results). The same can also be accessed by scanning the Quick Response (QR) Code provided below.

For Alembic Pharmaceuticals Limited
Sd/-
Chirayu Amin
Chairman and CEO

Place : Vadodara
Date : 6th May, 2025

Alembic
Touching Lives over 100 years

ALEMBIC PHARMACEUTICALS LIMITED

CIN: L24230GJ2010PLC061123
Regd.Office: Alembic Road, Vadodara - 390 003
Tel.: 0265 6637000
E-mail: apl.investors@alembic.co.in
Website: www.alembicpharmaceuticals.com

Extract of statement of Consolidated Audited Financial Results for the quarter & year ended 31st March, 2025

(₹ in Crores except per share data)

Particulars	Quarter Ended		Year Ended
	31.03.2025 (Audited)	31.03.2024 (Audited)	31.03.2025 (Audited)
Total Income from Operations	1,769.64	1,516.98	6,672.08
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	191.95	182.85	694.31
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	191.95	182.85	707.18
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items)	156.89	178.21	583.42
Total Comprehensive Income for the period	162.17	166.70	587.54
Equity Share Capital	39.31	39.31	39.31
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	—	—	5,151.63
Earning Per Share (Face Value of ₹2/- each) Basic & Diluted	7.98	9.07	29.68

Notes:

1.

Standalone details	Quarter Ended		Year Ended
	31.03.2025 (Audited)	31.03.2024 (Audited)	31.03.2025 (Audited)
Income from Operations	1,570.64	1,474.55	6,032.63
Profit Before Tax	91.56	216.16	595.72
Profit After Tax	75.34	201.87	503.12

2. The above is an extract of the detailed format of the audited financial results filed with the Stock Exchanges. The detailed Financial Results are available on the Stock Exchange's website at www.nseindia.com and www.bseindia.com and Company's website (URL: https://alembicpharmaceuticals.com/quarterly-results). The same can also be accessed by scanning the Quick Response (QR) Code provided below.

For Alembic Pharmaceuticals Limited
Sd/-
Chirayu Amin
Chairman and CEO

Place : Vadodara
Date : 6th May, 2025

MAS RURAL HOUSING & MORTGAGE FINANCE LIMITED

Narayan Chambers, 2nd Floor, B/h. Patang Hotel, Ashram Road, Ahmedabad-380009. Contact : 079-41106500/733

ડિમાન્ડ નોટીસ

સલામતીની કલમ ૧૩(૨) હેઠળ અને નાણાંકીય એસેટ્સની પુનનિર્માણ અને સુરક્ષાની સલામતી એક્ટ ૨૦૦૨(અધિનિયમ) સલામતી હિત (એન્ફોર્સમેન્ટ) રૂલ્સ ૨૦૦૨ - નિયમોના નિયમ 3 સાથે વાંચવા

આથી, માસ રૂરલ હાઉસીંગ એન્ડ મોર્ગેજ ફાઈનાન્સ લિમિટેડ દ્વારા નીચે સહી કરનાર અધિકૃત અધિકારી 'એક્ટની કલમ ૧૩ (૨)ની સાથે અધિનિયમોના અધિનિયમ ૩ ને વંચાણે લેતાં તેમને મળેલા પાવરનો ઉપયોગ કરતાં એક્ટની કલમ ૧૩ (૨) હેઠળ અરજદાર(રો) સહ અરજદાર(રો) જામીન(નો) (તમામને વ્યક્તિગત રીતે અથવા એક સાથે પ્રબંધનકર્તાઓ') કાયદેસરના વારસદાર(રો) કાયદેસરના પ્રતિનિધિ(ઓ) કે જેઓનાં નામ અત્રે નીચે જણાવેલ યાદીમાં આપવામાં આવેલ છે,ને આથી નીચે પાઠવવામાં આવેલ માંગણાં નોટિસ(સી)માં જણાવવામાં આવેલ અંતર્ગત દિન ૬૦માં નીચે દર્શાવવામાં આવેલી વિગતો અનુસાર ભરપાઈ કરી જવા માંગણી નોટિસ જેતે તારીખ નીચે દર્શાવેલ મુજબ એક્ટની કલમ ૧૩ (૨) હેઠળ જારી કરવામાં આવેલ છે. સદર નોટિસોની નકલો રજિસ્ટર્ડ પોસ્ટ એડીથી પાઠવવામાં આવેલ છે અને તે નીચે સહી કરનાર પાસે પણ મળી શકશે, અને સદર બંધનકર્તા(ઓ) કાયદેસરના વારસદાર(રો) કાયદેસરના પ્રતિનિધિ(ઓ), જો તેઓ ઇચ્છે તો સદર નકલ નીચે સહી કરનાર પાસેથી સામાન્ય કચેરીના કામના કલાક દરમિયાન મેળવી શકશે. ઉપરોક્તના અનુસંધાનમાં, આથી ફરી વખત નોટિસ આપવામાં આવે છે, કે બંધનકર્તા(ઓ) કાયદેસરના વારસદાર(રો) કાયદેસરના પ્રતિનિધિ(ઓ)એ સદર નોટિસ(સો) પાઠવ્યાના દિન ૬૦માં નીચે દર્શાવેલ સદરહુ નામો ધારણ કરનારાઓએ, તમામે એકસાથે નીચે કોલમમાં દર્શાવેલી વિગતો અનુસાર સંબંધિત તારીખે વધારાના વ્યાજ સાથે ચુકવણીની તારીખે અને/અથવા વસુલાત, ધિરાણ કરાર અને અન્ય દસ્તાવેજો, લખાણો સાથે વંચાણે લેતાં, જો કોઈ, સદર બંધનકર્તા(ઓ) દ્વારા અમલ બજવણી કરવામાં આવેલ હોઈ અહીં અત્રે નીચે દર્શાવવામાં આવેલી રકમ ભરપાઈ કરી જવી. ધિરાણની વસુલાતનાં બાકી લેણાં સામે MRHMFLને સદર બંધનકર્તા(ઓ)એ તારણ સંબંધે નીચે દર્શાવેલ સિકયોર્ડ એસેટ(સ) મુકેલ છે.

અરજદાર અને સહ-અરજદાર જામીનદારના નામ	મિલ્કતનું વર્ણન	લોન એકાઉન્ટ નંબર લેણી રકમ	ડિમાન્ડ નોટીસ તારીખ સ્ટીકીંગ નોટીસ તારીખ
નાનજીભાઈ મેરૂભાઈ સલાટ (અરજદાર) રમીલાબેન નાનજીભાઈ સલાટ (સહ-અરજદાર)	જત રજીસ્ટ્રેશન ડિસ્ટ્રીકટ સુરેન્દ્રનગર ખાતે આવેલ મોજે ગામ વઢવાણ, તા. વઢવાણ, જિલ્લો સુરેન્દ્રનગર ખાતે આવેલ રેવન્યુ સર્વે નં. ૨૧૨૭/પૈકી, પ્લોટ નં. ૧૬ અને ૧૭ કુલ ક્ષેત્રફળ ૩૩૦ ચો.મી. તેના સબ પ્લોટ નં. ૧૬+૧૭/૩ કે જેનું ક્ષેત્રફળ ૪૭.૧૪ ચો.મી. છે. તેવી બાંધકામ સહિતની તમામ મિલકત. **ચતુર્સીમા નીચે મુજબ : ટેકનિકલ મુજબ :** પૂર્વ : રોડ, પશ્ચિમ : ખુલ્લો પ્લોટ, ઉત્તર : સંલગ્ન મકાન, દક્ષિણ : સંલગ્ન મકાન. **ચતુર્સીમા નીચે મુજબ : વેચાણ ડીડ / દસ્તાવેજ મુજબ :** પૂર્વ : ૭.૫૦ મી. રોડ, પશ્ચિમ : પ્લોટ નં. ૨૬ અને ૨૭, ઉત્તર : એસ.પી. નં. ૧૬ + ૧૭/૪, દક્ષિણ : એસ.પી. નં. ૧૬ + ૧૭/૨.	લોન એકાઉન્ટ નં. : ૭૯૬૧ રૂા.૭,૪૬,૧૬૮.૦૦	તા.૦૨-૦૪-૨૦૨૫ તા. ૦૫-૦૫-૨૦૨૫

વધારાના વ્યાજ સાથે, વધુ ચોક્કસ રીતે સંબંધિત માંગણાં નોટિસમાં દર્શાવવામાં આવેલ આકસ્મિક ખર્ચા, ખર્ચ, અન્ય ચાર્જીસ વગેરે, ચુકવણીની તારીખ સુધી કરવામાં આવેલા ખર્ચા અને / અથવા પ્રતીત થયા અનુસાર દૂરવર્તી વ્યાજની ચુકવણીની તારીખ અને છે અથવા વસુલાતની તારીખ સુધી પૂરેપૂરા ભરપાઈ કરવાના રહેશે. જો સદર બંધનકર્તા(ઓ) MRHMFLને ઉપરોક્ત દર્શાવવામાં આવેલ નાણાંની ચુકવણી કરવામાં નિષ્ફળ જશે તો, સિકયુરિટી એસેટ(સ) સ્થાવર મિલકત(તો) સામે સદર એક્ટની કલમ ૧૩ (૪) હેઠળ અને લાગુ કરવામાં આવેલ નિયમો અનુસાર સંપૂર્ણ તથા સદર બંધનકર્તા(ઓ) કાયદેસરના વારસદાર(રો) કાયદેસરના પ્રતિનિધિ(ઓ) કાર્યવાહી કરશે જેના પરિણામો અને પડતર માટે તેઓ જવાબદાર રહેશે.

સદર બંધનકર્તા(ઓ)/કાયદેસરના વારસદાર(રો)કાયદેસરના પ્રતિનિધિ(ઓ) સદર એક્ટ હેઠળ ઉપરોક્ત તારણ પર મૂકેલી મિલકત(તો)સ્થાવર મિલકત(તો) વેચાણ, પટ્ટા પર અથવા અન્ય કોઈ રીતે લેખિત અગાઉથી લીધેલી પરવાનગી વિના હસ્તાંતર કરી શકશે નહીં.

તારીખ : ૦૭-૦૫-૨૦૨૫
સ્થળ : સુરેન્દ્રનગર

અધિકૃત અધિકારી
વતી, માસ રૂરલ હાઉસિંગ એન્ડ મોર્ગેજ ફાઇનાન્સ લિમિટેડ, શ્રી ભરત જે. ભટ્ટ (મો.) ૯૭૧૪૧૯૯૦૧૮

શિશ ઈન્ડસ્ટ્રીઝ લિમિટેડ

SHISH INDUSTRIES LTD
We make better...

સી.આઈ.એન.: એલ૨૫૨૦૯જીજે૨૦૧૭પીએલસી૦૯૭૨૭૩
રજીસ્ટર્ડ ઓફીસ: ૧૫૦૨, ૧૫મો માળ, જુનોમોનેટા ટાવર, પાલ આરટીઓ બીઆરટીએસ રોડ, રાજહંસ સિનેમા નજીક, અડાજણ ગામ, અડાજણ, સુરત-૩૯૫૦૦૯, ગુજરાત, ભારત.
ટેલિફોન: +૯૧ ૨૬૧ ૨૫૫ ૦૫૮૭ **ઈમેઈલ:** compliance@shishindustries.com **વેબસાઈટ:** www.shishindustries.com

૩૧મી, માર્ચ, ૨૦૨૫ના રોજ પૂરા થયેલા ત્રિમાસિક અને નાણાકીય વર્ષ ગાળાના એકીકૃત નાણાકીય પરિણામનો અર્ક

(ઈ.પી.એસ. સિવાય રકમ લાખમાં)

વિગતો	ત્રિમાસિક ગાળા ૩૧/૦૩/૨૦૨૫	નાણાકીય વર્ષ ૩૧/૦૩/૨૦૨૫	ત્રિમાસિક ગાળા ૩૧/૦૩/૨૦૨૪
	પાકા	પાકા	પાકા
કામગીરીમાંથી કુલ આવક	૩,૬૧૭.૨૫	૧૧,૯૮૫.૪૮	૨,૩૯૧.૭૭
સમયગાળા માટે ચોખ્ખો નફો / (નુકસાન) (કર, અપવાદરૂપ અને / અથવા અસામાન્ય વસ્તુઓ પહેલાં)	(૪૪.૫૬)	૭૯૧.૮૩	૪૫૨.૩૫
સમયગાળા માટે કર પહેલાંના ચોખ્ખો નફો / (નુકસાન) (અપવાદરૂપ અને / અથવા અસાધારણ વસ્તુઓ પછી)	(૪૪.૫૬)	૭૯૧.૮૩	૪૫૨.૩૫
સમયગાળા માટે કર પછીના ચોખ્ખો નફો / (નુકસાન) (અપવાદરૂપ અને / અથવા અસાધારણ વસ્તુઓ પછી)	૨૩૭.૭૨	૮૭૪.૦૩	૩૦૬.૩૯
સમયગાળા માટે કુલ વ્યાપક આવક [સમયગાળા માટે નફો / (નુકસાન) અને કરની બાદ અન્ય આવક (કર પછી) સમાવેશ થાય છે.]	૨૩૧.૯૨	૮૭૨.૯૨	૩૦૯.૭૮
ઈક્વિટી શેર મૂડી	૩,૭૯૫.૧૬	૩,૭૯૫.૧૬	૩,૫૦૦.૭૧
અનામત (પાછલા વર્ષના પાકા કરેલા સરવૈયા મુજબ મૂલ્યાંકન અનામતને બાદ કર્યા પછી)	–	૬,૩૪૭.૭૪	–
શેર દીઠ કમાણી (ચાલુ અને બંધ કામગીરી માટે)-			
બેઝીક: (સમાપ્ત ત્રિમાસિક ગાળા માટે વાર્ષિકીકરણ કર્યા વગર)	૦.૦૬	૦.૨૪	૦.૧૧
ઘટાડેલુ: (સમાપ્ત ત્રિમાસિક ગાળા માટે વાર્ષિકીકરણ કર્યા વગર)	૦.૦૬	૦.૨૪	૦.૧૧

નોંધ :

૧. ઉપરોક્ત નાણાકીય એ સેબી સૂચિઓ નિયમનોનાં નિયમન ૩૩ હેઠળ બીએસઈ લિમિટેડ સાથે ફાઈલ કરેલા ત્રિમાસિક અને નાણાકીય વર્ષ ગાળાના નાણાકીય પરિણામોના વિગતવાર બંધારણનો એક અર્ક છે.

૨. **એકલ પાકા નાણાકીય પરિણામોની વધારાની માહિતી નીચે મુજબ છે :** (રકમ લાખમાં)

વિગતો	ત્રિમાસિક ગાળા ૩૧/૦૩/૨૦૨૫	નાણાકીય વર્ષ ૩૧/૦૩/૨૦૨૫	ત્રિમાસિક ગાળા ૩૧/૦૩/૨૦૨૨
	પાકા	પાકા	પાકા
કામગીરીમાંથી કુલ આવક	૩,૯૩૭.૩૪	૧૨,૭૯૯.૮૨	૨,૬૦૯.૩૮
સમયગાળા માટે કર પહેલાંના ચોખ્ખો નફો / (નુકસાન) (અપવાદરૂપ અને / અથવા અસાધારણ વસ્તુઓ પછી)	૫૬૪.૬૬	૧,૪૬૭.૬૬	૫૩૩.૩૯
સમયગાળા માટે કર પછીના ચોખ્ખો નફો / (નુકસાન) (અપવાદરૂપ અને / અથવા અસાધારણ વસ્તુઓ પછી)	૪૧૨.૯૧	૧,૦૯૫.૨૧	૩૯૫.૧૬

૩. આખા નાણાકીય પરિણામો બીએસઈ લિમિટેડની વેબસાઈટ www.bseindia.com પર અને કંપનીની વેબસાઈટ www.shishindustries.com પર ઉપલબ્ધ છે. અને નીચે આપેલા QR કોડને સ્કેન કરીને તે એક્સેસ શકાય છે.

તારીખ: ૦૬/૦૫/૨૦૨૫
સ્થળ: સુરત

શિશ ઈન્ડસ્ટ્રીઝ લિમિટેડ વતિ
સહી/-
સતિષકુમાર માણિયા
ચેરમેન એન્ડ મેનેજીંગ ડિરેક્ટર
(સંચાલક ઓળખ નંબર: ૦૨૫૨૯૧૯૧)

પરિશિષ્ટ IV-એ,

સ્થાવર મિલકતના વેચાણ માટે સૂચના

સિક્યોરીટી ઈન્ટ્રેસ્ટ (એન્ફોર્સમેન્ટ) એક્ટ 2002ના નિયમ 8(6) અને નિયમ 9(1) મુજબ સિક્યોરિટાઈઝેશન એન્ડ રિકન્સ્ટ્રક્શન ઓફ ફાઈનાન્શિયલ એસેટ્સ એન્ડ એન્ફોર્સમેન્ટ ઓફ સિક્યોરીટી ઈન્ટ્રેસ્ટ એક્ટ 2002 હેઠળ સ્થાવર મિલકતના વેચાણ માટે ઈ-ઓક્શન વેચાણ સૂચના.

આ દ્વારા સામાન્ય જનતાને અને ખાસ કરીને કર્જદાર(રો) અને ગેરંટર(રો)ને સૂચના આપવામાં આવે છે કે, નીચે વર્ણન કરેલ સ્થાવર મિલકત કે જે **સમ્માન કૅપિટલ લિમિટેડ (આ પહેલા ઈન્ડિયાબુલ્સ હાઉસિંગ ફાઈનાન્સ લિ. તરીકે ઓળખાતી) [CIN : L65922DL2005PLC136029] (''સીક્યોર્ડ ક્રેડિટર'')** પાસે ગીરવે મુકેલ છે જેનો **વાસ્તવિક કબજો** સીક્યોર્ડ ક્રેડિટરના અધિકૃત અધિકારી દ્વારા લેવામાં આવ્યો છે તે **રૂ. 25,17,315/- (રૂપિયા પચ્ચીસ લાખ સત્તર હજાર ત્રણસો પંદર પૂરાં)** ની વસૂલી માટે **26.05.2025** ના રોજ **સાંજના 05.00 થી 06.00 વાગ્યા** દરમિયાન **''જેમ છે જ્યાં છે'', ''જેમ છે જે છે''** અને **''જે પણ જ્યાં છે''** ધોરણે વેચવામાં આવશે, જે **શ્રી. મિતિન મહેશભાઈ પંચાલ ઉર્ફે નિતિન પંચાલ, શ્રીમતી ઠાકોર નિકિતાબેન બાબુજી અને શ્રી. પંચાલ કિરણભાઈ મુકેશભાઈ** પાસેથી **લોન અકાઉન્ટ નં. HHLAHE00349228** માં બાકી નીકળતી મૂળ રકમ, એરીઅર્સ (જમા થયેલા લેટ ચાર્જિસ સહિત) તેમ જ **29.04.2025** સુધીનાં વ્યાજ સહિત લોન એગ્રીમેન્ટ અને અન્ય સંબંધિત લોન દસ્તાવેજ(જો)ની શરતો મુજબ **30.04.2025** થી અમલી બને તેમ લાગુ ભાવિ વ્યાજ ઉપરાંત કાનૂની ખર્ચ અને અન્ય ચાર્જિસ સહિત સીક્યોર્ડ ક્રેડિટરને ચૂકવવાના બાકી નીકળે છે.

સૂચિત પ્રોપર્ટીઓના ઓક્શન માટે અનામત કિંમત **રૂ. 14,54,400/- (રૂપિયા ચૌદ લાખ ચોપ્પન હજાર ચારસો પૂરાં)** છે. અને અર્નેસ્ટ મની ડિપોઝિટ **(''ઈએમડી'') રૂ. 1,45,440/- (રૂપિયા એક લાખ પિસ્તાલીસ હજાર ચારસો ચાલીસ પૂરાં)** એટલે અનામત મૂલ્ય 10 % ના બરાબર રહેશે.

સ્થાવર મિલકતનું વર્ણન

રહેણાંક મિલકત જે ફ્લેટ નં. 406 **ચોથા માળે, બ્લૉક ડી-**1 **(અમદાવાદ મ્યુનિસિપલ કૉર્પોરેશનના મંજૂર થયેલ પ્લાન મુજબ ત્રીજો માળ)માં આવેલ છે, જેનો વિસ્તાર** 52.10 **ચો. મીટર, બિલ્ટ-અપ એરિયા છે અને સંપૂર્ણ સ્કીમ માટે બાંધકામ પૈકી અને આ ફ્લેટ માટેના સરેરાશ અવિભાજિત જમીનના હિસ્સા જેનો વિસ્તાર** 19.13 **ચો. મીટરના સહિત છે, જે ''સર્ફેસ પેરેડાઇઝ'' તરીકે ઓળખાતી ફ્લેટ્સની સ્કીમમાં છે, જે બિન ખેતીની જમીન પર વિકસાવેલ છે જેનો રેવેન્યૂ સર્વે નં.** 374, **ખાતા નં.** 142 **હેક્ટર આરે ચો. મીટર** 1-26-47 **એ જમીનનો છે જે ટીપી સ્કીમ નં.** 104 **ઑફ ફાઇનલ પ્લૉટ નં.** 16 **બિન ખેતીની જમીન પર રહેણાંક હેતુ માટે છે જેનો વિસ્તાર** 7588 **ચો. મીટર ઑફ મોજે ગામ ઓઢવ સિમ તાલુકા સિટી અમદાવાદ વિભાગ-**7 **(ઓઢવ) પેટા જિલ્લા અમદાવાદમાં અને જિલ્લો અમદાવાદ, ગુજરાત -** 382350 **ની છે, જેની સીમાઓ નીચે મુજબ છે :**

પૂર્વમાં : ફ્લેટ નં. ડી1/401 **આવેલ છે, ઉત્તરમાં : બ્લૉક ડી આવેલ છે,**
પશ્ચિમમાં : ફ્લેટ નં. ડી1/405 **આવેલ છે, દક્ષિણમાં : ફ્લેટ નં. ડી**1/403 **આવેલ છે.**

વેચાણના વિસ્તૃત નિયમો અને શરતો માટે કૃપા કરી સીક્યોર્ડ ક્રેડિટર એટલે કે www.sammaancapital.com ની વેબસાઈટ પર આપેલી લિંક જુઓ; સંપર્ક નં. 0124 - 6910910, +91 7065451024; ઈ-મેલ આઈડી : auctionhelpline@sammaancapital.com. બિડિંગ માટે www.auctionfocus.in પર લૉગ ઑન કરો.

સહી/-
અધિકૃત અધિકારી
સમ્માન કૅપિટલ લિમિટેડ
(આ પહેલા ઈન્ડિયાબુલ્સ હાઉસિંગ ફાઈનાન્સ લિ. તરીકે ઓળખાતી)

તારીખ : 02.05.2025
સ્થળ : અમદાવાદ

ALEMBIC PHARMACEUTICALS LIMITED

Alembic — Touching Lives over 100 years

CIN: L24230GJ2010PLC061123
Regd.Office: Alembic Road, Vadodara - 390 003
Tel.: 0265 6637000
E-mail: apl.investors@alembic.co.in
Website: www.alembicpharmaceuticals.com

Extract of statement of Consolidated Audited Financial Results for the quarter & year ended 31st March, 2025

(₹ in Crores except per share data)

Particulars	Quarter Ended		Year Ended
	31.03.2025 (Audited)	31.03.2024 (Audited)	31.03.2025 (Audited)
Total Income from Operations	**1,769.64**	1,516.98	6,672.08
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	**191.95**	182.85	694.31
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	**191.95**	182.85	707.18
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items)	**156.89**	178.21	583.42
Total Comprehensive Income for the period	**162.17**	166.70	587.54
Equity Share Capital	**39.31**	39.31	39.31
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	—	—	5,151.63
Earning Per Share (Face Value of ₹2/- each) Basic & Diluted	**7.98**	9.07	29.68

Notes:

1. **Standalone details**

	Quarter Ended		Year Ended
	31.03.2025 (Audited)	31.03.2024 (Audited)	31.03.2025 (Audited)
Income from Operations	**1,570.64**	1,474.55	6,032.63
Profit Before Tax	**91.56**	216.16	595.72
Profit After Tax	**75.34**	201.87	503.12

2. The above is an extract of the detailed format of the audited financial results filed with the Stock Exchanges. The detailed Financial Results are available on the Stock Exchange's website at www.nseindia.com and www.bseindia.com and Company's website (URL: https://alembicpharmaceuticals.com/quarterly-results). The same can also be accessed by scanning the Quick Response (QR) Code provided below.

For Alembic Pharmaceuticals Limited
Sd/-
Chirayu Amin
Chairman and CEO

Place : Vadodara
Date : 6th May, 2025

PRE-OFFER ADVERTISEMENT AND CORRIGENDUM TO THE DETAILED PUBLIC STATEMENT UNDER REGULATION 18 (7) IN TERMS OF SEBI (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS) REGULATIONS, 2011

PROZONE REALTY LIMITED

Registered Office: Unit-A, 2nd Floor, South Tower, Hotel Sahara Star, Opposite Domestic Airport, Vile Parle (East), Mumbai- 400099, Maharashtra.
Corporate Identification Number (CIN): L45200MH2007PLC174147
Contact Number: +91 2268239000/9001; **Email Address:**investorservice@prozonerealty.com **Website:** www.prozonerealty.com

THIS ADVERTISEMENT CUM CORRIGENDUM TO THE DETAILED PUBLIC STATEMENT IS BEING ISSUED BY GRETEX CORPORATE SERVICES LIMITED, ("THE MANAGER TO THE OFFER"), ON BEHALF OF THE M/S. APAX TRUST (ACTING THROUGH ITS TRUSTEE – MR. NIKHIL CHATURVEDI) ("THE ACQUIRER"), FOR ACQUISITION OF UPTO 3,96,76,750 (THREE CRORE NINETY-SIX LAKH SEVENTY-SIX THOUSAND SEVEN HUNDRED FIFTY ONLY) FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹ 2.00/- EACH (INDIAN RUPEES TWO) ("OFFER SHARES") OF PROZONE REALTY LIMITED ("TARGET COMPANY" OR "TC") REPRESENTING 26.00% OF THE EQUITY AND VOTING SHARE CAPITAL FROM THE PUBLIC SHAREHOLDERS OF THE TARGET COMPANY PURSUANT TO AND IN COMPLIANCE WITH REGULATION 3(1) READ WITH REGULATIONS 13(4), 14(3) AND 15(2) OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS) REGULATIONS, 2011 ("SEBI SAST REGULATIONS") AS AMENDED FROM TIME TO TIME ("OPEN OFFER").

This Pre-Offer cum Corrigendum to the Detailed Public Advertisement is to be read in conjunction with the: a) Public Announcement dated Tuesday, December 31, 2024 (**"Public Announcement"**), (b) Detailed Public Statement dated Tuesday, January 07, 2025 (**"Detailed Public Statement"**), in connection with this Offer, published on behalf of Acquirer on Tuesday, January 07, 2025, in Financial Express (English Daily) (All Editions), Jansatta (Hindi Daily) (All Editions), and Mumbai Lakshadeep (Marathi Daily) (Mumbai Edition) (**"Newspapers"**), (c) Draft Letter of Offer dated Tuesday, January 14, 2025 filed and submitted with SEBI pursuant to the provisions of Regulation 16(1) of the SEBI (SAST) Regulations (**"Draft Letter of Offer"**), (d) Letter of Offer dated Friday, April 25, 2025 (**"Letter of Offer"**), (e) Recommendations of Independent Directors of the Company which were approved on Wednesday, April 30, 2025 and published in the Newspapers on Sunday, May 04, 2025 (**"Recommendations of the Independent Directors of the Target Company"**).

The Public Announcement, Detailed Public Statement, Draft Letter of Offer, Letter of Offer, Recommendations of the Independent Directors, and this Pre-Offer Advertisement cum Corrigendum to the Detailed Public Statement of the Target Company are hereinafter collectively referred to as "Offer Documents" issued by the Manager on behalf of the Acquirer.

Public Shareholders of the Target Company are requested to kindly note the following:

For capitalized terms used hereinafter, please refer to the paragraph 1 titled as "Definitions/Abbreviations" of the Letter of Offer.

1. Offer Price:

The Offer is being made at a price of ₹ 25/- (Indian Rupees Twenty-Five Only) per Equity Share ("Offer Price"). There has been no revisions in the Offer Price.

2. Recommendations of the Committee of Independent Directors of the Target Company:

A Committee of Independent Directors of the Target Company (**"IDC"**) comprising of Mr. Umesh Kumar, as the Chairperson of the IDC, Mrs. Deepa Misra Harris and Mrs. Dipa Hetal Hakani, as members of IDC approved their recommendation on the Offer on Wednesday, April 30, 2025 and published in the Newspaper on Sunday, 04 May 2025, in the same newspapers where the DPS was published. Based on the review, IDC Members believe that the Offer is fair and reasonable and in line with the SEBI SAST Regulations. However, the shareholders may independently evaluate the Offer, the market performance of the Equity Shares and then take an informed decision in the best of their interests.

3. Other details with respect to Offer

a. The Offer is not a competing offer in terms of Regulation 20 of SEBI SAST Regulations. There was no competing offer to the Offer and the last date for making such competing offer has expired. The Offer is not conditional upon any minimum level of acceptance in terms of Regulation 19(1) of SEBI SAST Regulations

b. The Letter of Offer has been dispatched to the Public Shareholders of the Target Company whose name appear on Wednesday, April 23, 2025, being the identified date.

i. On Friday, April 25, 2025, through electronic mode to all the Public Shareholders whose e-mail addresses had been registered with the Depositories/Target Company.

ii. On Wednesday, April 30, 2025 through registered post to those Public Shareholders who have not registered their email address with the Depositories/Target Company.

c. The Draft Letter of Offer dated Tuesday, January 14, 2025, was filed and submitted with SEBI pursuant to the provisions of Regulation 16(1) of the SEBI (SAST) Regulations, for its Observations. In pursuance of which all the observations received from SEBI vide letter bearing reference number SEBI/HO/CFD-RAC-DCR1/P/OW/2025/11138/1 dated Monday, April 21, 2025, which have been incorporated in the Letter of Offer. There have been no other material changes in relation to the Offer, as otherwise disclosed in the Letter of Offer.

d. Dispatch of Letter of Offer to the public shareholders.

The dispatch of the Letter of Offer to all the Public Shareholders of the Target Company holding Equity Shares as on the Identified Date i.e. Wednesday, April 23, 2025 has been completed (either through electronic or physical mode) by Wednesday, April 30, 2025. The Identified Date was relevant only for the purpose of determining the Public Shareholders as on such date to whom the Letter of Offer was to be sent. It is clarified that all the Public Shareholders of Equity Shares (except the Acquirer and parties to SPA) as on the Identified Date are eligible to participate in the Offer any time during the Tendering Period. A copy of the Letter of Offer (which includes the Form of Acceptance-cum-Acknowledgment) is also available on SEBI's website (www.sebi.gov.in) and the Website of the Manager to the Offer (www.gretexcorporate.com) from which the Public Shareholders can download/print the same.

e. Instructions to the public shareholders

i. In case the shares are held in physical form

As per the provisions of Regulation 40(1) of the SEBI (LODR) Regulations and SEBI's press release dated December 3, 2018, bearing reference no. PR 49/2018, requests for transfer of securities shall not be processed unless the securities are held in dematerialised form with a depository with effect from April 1, 2019. However, in accordance with the circular issued by SEBI bearing reference number SEBI/HO/CFD/CMD1/CIR/P/2020/144 dated July 31, 2020, shareholders holding securities in physical form are allowed to tender shares in an open offer. Such tendering shall be as per the provisions of the SEBI (SAST) Regulations. An eligible shareholder may participate in this Offer by approaching their respective Selling Broker and tender their shares in the open offer as per the procedure as mentioned in the Letter of Offer along with other details.

ii. In case the shares are held in demat form

An eligible shareholder may participate in this Offer by approaching their Selling Broker and tender their shares in the open offer as per the procedure as mentioned in the Letter of Offer along with other details.

iii. Procedure for Tendering the Shares in case of Non-Receipt of the Letter of Offer

Persons who have acquired Equity Shares but whose names do not appear in the register of members of the Target Company on the Identified Date, or unregistered owners or those who have acquired Equity Shares after the Identified Date, or those who have not received the Letter of Offer, may also participate in this Offer.

In case of non-receipt of the Letter of Offer, the Shareholders holding the Equity Shares may participate in the Offer by providing their application in plain paper in writing signed by all shareholder(s), along with the following details:

- **In case of physical shares:** Name, address, distinctive numbers, folio nos, number of Equity Shares tendered/withdrawn.
- **In case of dematerialized shares:** Name, address, number of Equity Shares tendered/withdrawn, DP name, DP ID number, Beneficiary account no., and other relevant documents as mentioned in the Letter of Offer. Such Shareholders have to ensure that their order is entered in the electronic platform of BSE through the Selling broker which will be made available by BSE before the closure of the Tendering Period.

f. The Open Offer will be implemented by the Acquirer through Stock Exchange Mechanism made available by the Stock Exchanges in the form of separate window ("Acquisition Window") as provided under the SEBI (SAST) Regulations, 2011 and SEBI circular CIR/CFD/POLICYCELL/1/2015 dated April 13, 2015 issued by SEBI as amended via SEBI circular CFD/DCR2/ CIR/P/2016/131 dated December 09, 2016 and SEBI circular SEBI/HO/CFD/ DCRIII/CIR/P/2021/615 dated August 13, 2021, as amended, including any guidelines and circulars issued in relation to the same by the Stock Exchange, clearing corporations and SEBI ("Acquisition Window Circulars").

g. The marketable lot for the Equity Shares of the Target Company is 1 (One) Equity Share.

h. Any other material change from date of the Public Announcement- None

i. Corrigendum to the Detailed Public Statement (DPS)

(i) The date mentioned as Thursday, February 06, 2024 under Section (I)(D) - Details of the Offer, shall be read and construed as Thursday, February 06, 2025.

(ii) The schedule of activities as listed under Section (VII)- Tentative Schedule of the activities pertaining to the Offer shall stand revised with the Schedule of Activities as listed under section 11 of this Pre-Offer Advertisement.

j. Details regarding the status of the Statutory and other approvals

To the best of the knowledge of the Acquirer, there are no statutory approvals required for the purpose of this Offer. If any statutory approvals become applicable prior to the completion of the Offer, the Offer would also be subject to such statutory approvals. The Acquirer will not proceed with the Offer in the event such statutory approvals are refused in terms of Regulation 23 of the SEBI SAST Regulations.

k. Schedule of Activities:

The Schedule of Activities have been revised and the necessary changes have been incorporated in the LoF. The Revised Schedule of Activities is in compliance with the applicable provisions of SEBI (SAST) Regulations, 2011 and the same is as under:

Activities	Day and Date (Actual)	Day and Date (Revised)
Public Announcement	Tuesday, December 31, 2024	Tuesday, December 31, 2024
Publication of Detailed Public Statement in newspapers	Tuesday, January 07, 2025	Tuesday, January 07, 2025
Last Date of Filing of Draft Letter of Offer with SEBI	Tuesday, January 14, 2025	Tuesday, January 14, 2025
Last Date for public announcement of a competing offer#	Tuesday, January 28, 2025	Tuesday, January 28, 2025
Receipt of comments from SEBI on Draft Letter of Offer	Tuesday, February 04, 2025	Monday, April 21, 2025
Identified Date*	Tuesday, February 06, 2025	Wednesday, April 23, 2025
Date by which Letter of Offer will be dispatched to the Public Shareholders	Thursday, February 13, 2025	Wednesday, April 30, 2025
Last day of revision of Offer Price / Offer Size	Thursday, February 13, 2025	Tuesday, May 06, 2025
Date of issue of advertisement announcing the schedule of activities for Open Offer, status of statutory and other approvals in newspapers	Wednesday, February 19, 2025	Wednesday, May 07, 2025
Date of commencement of Tendering Period (**"Offer Opening Date"**)	Thursday, February 20, 2025	Thursday, May 08, 2025
Date of closure of Tendering Period (**"Offer Closing Date"**)	Friday, March 07, 2025	Thursday, May 22, 2025
Date of communicating the rejection / acceptance and payment of consideration for the accepted Offer Shares / return of unacquired Offer Shares	Monday, March 24, 2025	Thursday, June 05, 2025
Issuance of post offer advertisement	Tuesday, April 01, 2025	Thursday, June 12, 2025
Last Date of filing the final report to SEBI	Wednesday, April 02, 2025	Thursday, June 12, 2025

Note:

1. *The original schedule of activities was indicative (prepared on the basis of timelines provided under the SEBI (SAST) Regulations). Where last dates are mentioned for certain activities, such activities may take place on or before the respective last dates.*
2. *There has been no competing offer as of the date of this Advertisement.*
3. *Identified Date refers to the date falling on the 10th Working Day prior to the commencement of the Tendering Period. The Identified Date is only for the purpose of determining the Public Shareholders to whom the Letter of Offer would be sent in accordance with the SEBI (SAST) Regulations. It is clarified that all Public Shareholders are eligible to participate in the Offer any time during the Tendering Period.*

4. Other information

The Acquirer accepts full responsibility for the obligations as laid down in the SEBI SAST Regulations and for the information contained in this Pre-Offer Advertisement and Corrigendum to the Detailed Public Statement.

This Pre-Offer Advertisement and Corrigendum to the Detailed Public Statement would also be available on SEBI's website at www.sebi.gov.in, the Target Company at www.prozonerealty.com; the Registrar to the Offer at www.linkintime.co.in , and Manager to the Offer at www.gretexcorporate.com.

Issued by Manager to the Offer on behalf of the Acquirer

GRETEX

GRETEX CORPORATE SERVICES LIMITED
A-401, Floor 4th , Plot FP-616, (PT), Naman Midtown, Senapati Bapat Marg, Near Indiabulls, Dadar (w), Delisle Road, Maharashtra- 400013, India,
Tel No.: 022-69308500 **Email:** info@gretexgroup.com
Website: www.gretexcorporate.com **Contact Person:** Mr. Arvind Harlalka
SEBI Registration No: INM000012177 **CIN:** L74999MH2008PLC288128

Acquirer
M/s. Apax Trust (represented by its Trustee – Mr. Nikhil Chaturvedi)
Sd/-
Place: Mumbai
Date: 06 May, 2025